Semmelweis University
semmelweis.huTotal trials
153
Active
47
Phase 3
7
Total enrollment
67,802
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 17 of 17 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Hydrocortisone | — | — | — | — | 2 | ||
| Elixirium thymi compositum | — | — | — | — | — | 1 | |
| Elixirium thymi compositum (FoNo VIII.) placebo | — | — | — | — | — | 1 | |
| Caffeine citrate | — | — | — | — | — | 1 | |
| Extended infusion time of the following beta-lactam: meropenem | — | — | — | — | — | 1 | |
| Short-term infusion time of the following beta-lactam: meropenem | — | — | — | — | — | 1 | |
| Extended infusion time of the following beta-lactam: piperacillin/tazobactam | — | — | — | — | — | 1 | |
| Extended infusion time of the following beta-lactam: cefepime | — | — | — | — | — | 1 | |
| Extended infusion time of the following beta-lactam: ceftriaxone | — | — | — | — | — | 1 | |
| Short-term infusion time of the following beta-lactam: piperacillin/tazobactam | — | — | — | — | — | 1 | |
| Short-term infusion time of the following beta-lactam: cefepime | — | — | — | — | — | 1 | |
| Short-term infusion time of the following beta-lactam: ceftriaxone | — | — | — | — | — | 1 | |
| Paclitaxel | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Cyclophosphamide/Doxorubicin | — | — | — | — | — | 1 | |
| Intranasal breast milk | — | — | — | — | — | 2 | |
| Acetylcholine Chloride | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2025-09-22
- 2025-10-31
- 2027-06
- 2027-09
- 2027-12
- 2028-01
- 2028-04
Top conditions
- Coronary Artery Disease4
- Oral Soft Tissue Conditions4
- Endometriosis4
- Vitamin D Deficiency3
- Alveolar Bone Loss3
- Perinatal Asphyxia3
- Chronic Heart Failure3
- Cardiac Surgery3
Frequently asked questions about Semmelweis University
- How many clinical trials does Semmelweis University have on ClinicalTrials.gov?
- Semmelweis University is listed as the lead sponsor on 153 clinical trials in ClinicalTrials.gov, 47 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Semmelweis University's trials are in Phase 3?
- 7 of Semmelweis University's trials are in Phase 3, spread across 17 active drug programs.
- What therapeutic areas does Semmelweis University focus on?
- Semmelweis University's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Oral Soft Tissue Conditions, Endometriosis, Vitamin D Deficiency, Alveolar Bone Loss.
- When are Semmelweis University's next clinical trial readouts?
- Semmelweis University has 8 upcoming primary-completion readouts tracked here; the soonest is “Investigation of Endothelium-dependent Vasodilation in Human Gingiva”, expected around 2024-12-31.